ID   PON1_HUMAN              Reviewed;         355 AA.
AC   P27169; B2RA40; Q16052; Q6B0J6; Q9UCB1;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   05-OCT-2010, sequence version 3.
DT   07-APR-2021, entry version 214.
DE   RecName: Full=Serum paraoxonase/arylesterase 1 {ECO:0000303|PubMed:7916578};
DE            Short=PON 1 {ECO:0000303|PubMed:15772423};
DE            EC=3.1.1.2 {ECO:0000269|PubMed:15098021, ECO:0000269|PubMed:15772423, ECO:0000269|PubMed:1673382, ECO:0000269|PubMed:1718413, ECO:0000269|PubMed:8393742};
DE            EC=3.1.1.81 {ECO:0000269|PubMed:15098021, ECO:0000269|PubMed:15772423};
DE            EC=3.1.8.1 {ECO:0000269|PubMed:15098021, ECO:0000269|PubMed:15772423, ECO:0000269|PubMed:1673382, ECO:0000269|PubMed:1718413, ECO:0000269|PubMed:8393742};
DE   AltName: Full=Aromatic esterase 1;
DE            Short=A-esterase 1;
DE   AltName: Full=K-45;
DE   AltName: Full=Serum aryldialkylphosphatase 1;
GN   Name=PON1; Synonyms=PON;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS MET-55 AND ARG-192.
RC   TISSUE=Liver;
RX   PubMed=1657140; DOI=10.1021/bi00106a010;
RA   Hassett C., Richter R.J., Humbert R., Chapline C., Crabb J.W.,
RA   Omiecinski C.J., Furlong C.E.;
RT   "Characterization of cDNA clones encoding rabbit and human serum
RT   paraoxonase: the mature protein retains its signal sequence.";
RL   Biochemistry 30:10141-10149(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], POLYMORPHISM, AND VARIANTS MET-55 AND
RP   ARG-192.
RX   PubMed=7916578;
RA   Adkins S., Gan K.N., Mody M., La Du B.N.;
RT   "Molecular basis for the polymorphic forms of human serum
RT   paraoxonase/arylesterase: glutamine or arginine at position 191, for the
RT   respective A or B allozymes.";
RL   Am. J. Hum. Genet. 52:598-608(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], CATALYTIC ACTIVITY, AND VARIANTS MET-55 AND
RP   ARG-192.
RC   TISSUE=Liver;
RX   PubMed=8393742; DOI=10.1016/0009-2797(93)90022-q;
RA   La Du B.N., Adkins S., Kuo C.L., Lipsig D.;
RT   "Studies on human serum paraoxonase/arylesterase.";
RL   Chem. Biol. Interact. 87:25-34(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], VARIANTS MET-55 AND ARG-192, AND
RP   CHARACTERIZATION.
RC   TISSUE=Liver;
RX   PubMed=8393745; DOI=10.1016/0009-2797(93)90023-r;
RA   Furlong C.E., Costa L.G., Hassett C., Richter R.J., Sundstrom J.A.,
RA   Adler D.A., Disteche C.M., Omiecinski C.J., Chapline C., Crabb J.W.;
RT   "Human and rabbit paraoxonases: purification, cloning, sequencing, mapping
RT   and role of polymorphism in organophosphate detoxification.";
RL   Chem. Biol. Interact. 87:35-48(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT MET-55.
RC   TISSUE=Lymphoblast;
RX   PubMed=8812495; DOI=10.1006/geno.1996.0401;
RA   Clendenning J.B., Humbert R., Green E.D., Wood C., Traver D., Furlong C.E.;
RT   "Structural organization of the human PON1 gene.";
RL   Genomics 35:586-589(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=9261565; DOI=10.1038/cr.1997.9;
RA   Wang K.K., Wan D.F., Qiu X.K., Lu P.X., Gu J.R.;
RT   "Differential expression of a cDNA clone in human liver versus hepatic
RT   cancer -- highly homologous to aryl-dialkyl-phosphatase.";
RL   Cell Res. 7:79-90(1997).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT MET-55.
RC   TISSUE=Liver;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ARG-192.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (AUG-2002) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   PROTEIN SEQUENCE OF 2-21, AND TISSUE SPECIFICITY.
RX   PubMed=8382160; DOI=10.1111/j.1432-1033.1993.tb17620.x;
RA   Blatter M.-C., James R.W., Messmer S., Barja F., Pometta D.;
RT   "Identification of a distinct human high-density lipoprotein subspecies
RT   defined by a lipoprotein-associated protein, K-45. Identity of K-45 with
RT   paraoxonase.";
RL   Eur. J. Biochem. 211:871-879(1993).
RN   [14]
RP   PROTEIN SEQUENCE OF 2-21; 234-244; 291-305 AND 350-355, INTERACTION WITH
RP   CLU, TISSUE SPECIFICITY, AND DISULFIDE BOND.
RC   TISSUE=Plasma;
RX   PubMed=8292612; DOI=10.1021/bi00169a026;
RA   Kelso G.J., Stuart W.D., Richter R.J., Furlong C.E., Jordan-Starck T.C.,
RA   Harmony J.A.K.;
RT   "Apolipoprotein J is associated with paraoxonase in human plasma.";
RL   Biochemistry 33:832-839(1994).
RN   [15]
RP   PROTEIN SEQUENCE OF 2-11, AND CATALYTIC ACTIVITY.
RX   PubMed=1718413; DOI=10.1021/bi00106a009;
RA   Furlong C.E., Richter R.J., Chapline C., Crabb J.W.;
RT   "Purification of rabbit and human serum paraoxonase.";
RL   Biochemistry 30:10133-10140(1991).
RN   [16]
RP   CATALYTIC ACTIVITY.
RX   PubMed=1673382;
RA   Gan K.N., Smolen A., Eckerson H.W., La Du B.N.;
RT   "Purification of human serum paraoxonase/arylesterase. Evidence for one
RT   esterase catalyzing both activities.";
RL   Drug Metab. Dispos. 19:100-106(1991).
RN   [17]
RP   MUTAGENESIS OF CYS-284.
RX   PubMed=7638166; DOI=10.1073/pnas.92.16.7187;
RA   Sorenson R.C., Primo-Parmo S.L., Kuo C.-L., Adkins S., Lockridge O.,
RA   La Du B.N.;
RT   "Reconsideration of the catalytic center and mechanism of mammalian
RT   paraoxonase/arylesterase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:7187-7191(1995).
RN   [18]
RP   MUTAGENESIS OF 20-HIS-GLN-21, AND FUNCTION OF THE UNCLEAVED SIGNAL PEPTIDE.
RX   PubMed=10479665; DOI=10.1161/01.atv.19.9.2214;
RA   Sorenson R.C., Bisgaier C.L., Aviram M., Hsu C., Billecke S., La Du B.N.;
RT   "Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal
RT   leader sequence associates with HDLs by binding phospholipids:
RT   apolipoprotein A-I stabilizes activity.";
RL   Arterioscler. Thromb. Vasc. Biol. 19:2214-2225(1999).
RN   [19]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-253.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [20]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBUNIT.
RX   PubMed=15772423; DOI=10.1194/jlr.m400511-jlr200;
RA   Draganov D.I., Teiber J.F., Speelman A., Osawa Y., Sunahara R., La Du B.N.;
RT   "Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping
RT   and distinct substrate specificities.";
RL   J. Lipid Res. 46:1239-1247(2005).
RN   [21]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-253 AND ASN-324.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [22]
RP   INTERACTION WITH HPBP.
RX   PubMed=16531243; DOI=10.1016/j.str.2005.12.012;
RA   Morales R., Berna A., Carpentier P., Contreras-Martel C., Renault F.,
RA   Nicodeme M., Chesne-Seck M.-L., Bernier F., Dupuy J., Schaeffer C.,
RA   Diemer H., van Dorsselaer A., Fontecilla-Camps J.C., Masson P., Rochu D.,
RA   Chabriere E.;
RT   "Serendipitous discovery and X-ray structure of a human phosphate binding
RT   apolipoprotein.";
RL   Structure 14:601-609(2006).
RN   [23]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-253 AND ASN-324.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) IN COMPLEX WITH CALCIUM IONS,
RP   MUTAGENESIS OF HIS-115 AND HIS-134, CATALYTIC ACTIVITY, AND DISULFIDE BOND.
RX   PubMed=15098021; DOI=10.1038/nsmb767;
RA   Harel M., Aharoni A., Gaidukov L., Brumshtein B., Khersonsky O., Meged R.,
RA   Dvir H., Ravelli R.B.G., McCarthy A., Toker L., Silman I., Sussman J.L.,
RA   Tawfik D.S.;
RT   "Structure and evolution of the serum paraoxonase family of detoxifying and
RT   anti-atherosclerotic enzymes.";
RL   Nat. Struct. Mol. Biol. 11:412-419(2004).
RN   [26]
RP   POLYMORPHISM, VARIANT ARG-192, AND CHARACTERIZATION OF VARIANT ARG-192.
RX   PubMed=8098250; DOI=10.1038/ng0193-73;
RA   Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J.,
RA   Furlong C.E.;
RT   "The molecular basis of the human serum paraoxonase activity
RT   polymorphism.";
RL   Nat. Genet. 3:73-76(1993).
RN   [27]
RP   ASSOCIATION WITH DIABETIC RETINOPATHY SUSCEPTIBILITY.
RX   PubMed=9661650; DOI=10.1210/jcem.83.7.5096;
RA   Kao Y.-L., Donaghue K., Chan A., Knight J., Silink M.;
RT   "A variant of paraoxonase (PON1) gene is associated with diabetic
RT   retinopathy in IDDM.";
RL   J. Clin. Endocrinol. Metab. 83:2589-2592(1998).
RN   [28]
RP   VARIANT VAL-102.
RX   PubMed=12783936; DOI=10.1093/jnci/95.11.812;
RA   Marchesani M., Hakkarainen A., Tuomainen T.P., Kaikkonen J., Pukkala E.,
RA   Uimari P., Seppala E., Matikainen M., Kallioniemi O.-P., Schleutker J.,
RA   Lehtimaki T., Salonen J.T.;
RT   "New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in
RT   Finnish men.";
RL   J. Natl. Cancer Inst. 95:812-818(2003).
RN   [29]
RP   VARIANT [LARGE SCALE ANALYSIS] ARG-192.
RX   PubMed=18987736; DOI=10.1038/nature07485;
RA   Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K.,
RA   Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L.,
RA   Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A.,
RA   Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V.,
RA   Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R.,
RA   Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E.,
RA   Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J., Heath S.,
RA   Shannon W.D., Nagarajan R., Walter M.J., Link D.C., Graubert T.A.,
RA   DiPersio J.F., Wilson R.K.;
RT   "DNA sequencing of a cytogenetically normal acute myeloid leukaemia
RT   genome.";
RL   Nature 456:66-72(2008).
CC   -!- FUNCTION: Hydrolyzes the toxic metabolites of a variety of
CC       organophosphorus insecticides. Capable of hydrolyzing a broad spectrum
CC       of organophosphate substrates and lactones, and a number of aromatic
CC       carboxylic acid esters. Mediates an enzymatic protection of low density
CC       lipoproteins against oxidative modification and the consequent series
CC       of events leading to atheroma formation. {ECO:0000269|PubMed:10479665,
CC       ECO:0000269|PubMed:15772423}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a phenyl acetate + H2O = a phenol + acetate + H(+);
CC         Xref=Rhea:RHEA:17309, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30089, ChEBI:CHEBI:33853, ChEBI:CHEBI:140310; EC=3.1.1.2;
CC         Evidence={ECO:0000269|PubMed:15098021, ECO:0000269|PubMed:15772423,
CC         ECO:0000269|PubMed:1673382, ECO:0000269|PubMed:1718413,
CC         ECO:0000269|PubMed:8393742};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=An aryl dialkyl phosphate + H(2)O = dialkyl phosphate + an
CC         aryl alcohol.; EC=3.1.8.1; Evidence={ECO:0000269|PubMed:15098021,
CC         ECO:0000269|PubMed:15772423, ECO:0000269|PubMed:1673382,
CC         ECO:0000269|PubMed:1718413, ECO:0000269|PubMed:8393742};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=an N-acyl-L-homoserine lactone + H2O = an N-acyl-L-homoserine
CC         + H(+); Xref=Rhea:RHEA:22576, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:55474, ChEBI:CHEBI:58921; EC=3.1.1.81;
CC         Evidence={ECO:0000269|PubMed:15098021, ECO:0000269|PubMed:15772423};
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC       Note=Binds 2 calcium ions per subunit.;
CC   -!- SUBUNIT: Homodimer. Heterooligomer with phosphate-binding protein
CC       (HPBP). Interacts with CLU. {ECO:0000269|PubMed:15098021,
CC       ECO:0000269|PubMed:15772423, ECO:0000269|PubMed:16531243,
CC       ECO:0000269|PubMed:8292612}.
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space.
CC   -!- TISSUE SPECIFICITY: Plasma, associated with HDL (at protein level).
CC       Expressed in liver, but not in heart, brain, placenta, lung, skeletal
CC       muscle, kidney or pancreas. {ECO:0000269|PubMed:8292612,
CC       ECO:0000269|PubMed:8382160}.
CC   -!- PTM: Glycosylated. {ECO:0000269|PubMed:14760718,
CC       ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:19159218}.
CC   -!- PTM: The signal sequence is not cleaved.
CC   -!- PTM: Present in two forms, form B contains a disulfide bond, form A
CC       does not.
CC   -!- POLYMORPHISM: The allelic form of the enzyme with Gln-192 (allozyme A)
CC       hydrolyzes paraoxon with a low turnover number and the one with Arg-192
CC       (allozyme B) with a high turnover number. {ECO:0000269|PubMed:7916578,
CC       ECO:0000269|PubMed:8098250}.
CC   -!- DISEASE: Microvascular complications of diabetes 5 (MVCD5)
CC       [MIM:612633]: Pathological conditions that develop in numerous tissues
CC       and organs as a consequence of diabetes mellitus. They include diabetic
CC       retinopathy, diabetic nephropathy leading to end-stage renal disease,
CC       and diabetic neuropathy. Diabetic retinopathy remains the major cause
CC       of new-onset blindness among diabetic adults. It is characterized by
CC       vascular permeability and increased tissue ischemia and angiogenesis.
CC       Note=Disease susceptibility is associated with variants affecting the
CC       gene represented in this entry. Homozygosity for the Leu-55 allele is
CC       strongly associated with the development of retinal disease in diabetic
CC       patients.
CC   -!- MISCELLANEOUS: The preferential association of PON1 with HDL is
CC       mediated in part by its signal peptide, by binding phospholipids
CC       directly, rather than binding apo AI. The retained signal peptide may
CC       allow transfer of the protein between phospholipid surfaces.
CC   -!- SIMILARITY: Belongs to the paraoxonase family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/pon1/";
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=PON1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M63012; AAB59538.1; -; mRNA.
DR   EMBL; M63013; AAA60142.1; -; mRNA.
DR   EMBL; M63014; AAA60143.1; -; mRNA.
DR   EMBL; S56555; AAB25717.1; -; Genomic_DNA.
DR   EMBL; S56546; AAB25717.1; JOINED; Genomic_DNA.
DR   EMBL; S56548; AAB25717.1; JOINED; Genomic_DNA.
DR   EMBL; S64696; AAB27899.1; -; mRNA.
DR   EMBL; S64615; AAB27714.2; -; mRNA.
DR   EMBL; U55885; AAB41835.1; -; Genomic_DNA.
DR   EMBL; U55877; AAB41835.1; JOINED; Genomic_DNA.
DR   EMBL; U55878; AAB41835.1; JOINED; Genomic_DNA.
DR   EMBL; U55879; AAB41835.1; JOINED; Genomic_DNA.
DR   EMBL; U55880; AAB41835.1; JOINED; Genomic_DNA.
DR   EMBL; U55881; AAB41835.1; JOINED; Genomic_DNA.
DR   EMBL; U55882; AAB41835.1; JOINED; Genomic_DNA.
DR   EMBL; U55883; AAB41835.1; JOINED; Genomic_DNA.
DR   EMBL; D84371; BAA12327.1; -; mRNA.
DR   EMBL; U53784; AAA97957.1; -; mRNA.
DR   EMBL; Z70723; CAA94728.1; -; mRNA.
DR   EMBL; AK314027; BAG36737.1; -; mRNA.
DR   EMBL; AF539592; AAM97935.1; -; Genomic_DNA.
DR   EMBL; AC004022; AAC35293.1; -; Genomic_DNA.
DR   EMBL; CH236949; EAL24133.1; -; Genomic_DNA.
DR   EMBL; CH471091; EAW76771.1; -; Genomic_DNA.
DR   EMBL; BC074719; AAH74719.1; -; mRNA.
DR   CCDS; CCDS5638.1; -.
DR   PIR; A45451; A45451.
DR   RefSeq; NP_000437.3; NM_000446.5.
DR   PDB; 1V04; X-ray; 2.20 A; A=1-353.
DR   PDB; 1XHR; Model; -; A=40-355.
DR   PDBsum; 1V04; -.
DR   PDBsum; 1XHR; -.
DR   SMR; P27169; -.
DR   BioGRID; 111440; 9.
DR   IntAct; P27169; 6.
DR   STRING; 9606.ENSP00000222381; -.
DR   BindingDB; P27169; -.
DR   ChEMBL; CHEMBL3167; -.
DR   DrugBank; DB01327; Cefazolin.
DR   DrugBank; DB09130; Copper.
DR   DrugBank; DB01395; Drospirenone.
DR   DrugBank; DB14598; Edetate calcium disodium anhydrous.
DR   DrugBank; DB14600; Edetate disodium anhydrous.
DR   DrugBank; DB14596; Loteprednol etabonate.
DR   DrugBank; DB01593; Zinc.
DR   DrugBank; DB14487; Zinc acetate.
DR   DrugBank; DB14533; Zinc chloride.
DR   DrugBank; DB14548; Zinc sulfate, unspecified form.
DR   TCDB; 1.A.6.2.6; the epithelial na(+) channel (enac) family.
DR   GlyConnect; 726; 21 N-Linked glycans (3 sites).
DR   GlyGen; P27169; 4 sites, 12 N-linked glycans (2 sites).
DR   iPTMnet; P27169; -.
DR   PhosphoSitePlus; P27169; -.
DR   BioMuta; PON1; -.
DR   DMDM; 308153572; -.
DR   SWISS-2DPAGE; P27169; -.
DR   CPTAC; CPTAC-2233; -.
DR   CPTAC; non-CPTAC-2695; -.
DR   jPOST; P27169; -.
DR   MassIVE; P27169; -.
DR   MaxQB; P27169; -.
DR   PaxDb; P27169; -.
DR   PeptideAtlas; P27169; -.
DR   PRIDE; P27169; -.
DR   ProteomicsDB; 54376; -.
DR   Antibodypedia; 883; 609 antibodies.
DR   Ensembl; ENST00000222381; ENSP00000222381; ENSG00000005421.
DR   GeneID; 5444; -.
DR   KEGG; hsa:5444; -.
DR   UCSC; uc003uns.4; human.
DR   CTD; 5444; -.
DR   DisGeNET; 5444; -.
DR   GeneCards; PON1; -.
DR   HGNC; HGNC:9204; PON1.
DR   HPA; ENSG00000005421; Tissue enriched (liver).
DR   MalaCards; PON1; -.
DR   MIM; 168820; gene+phenotype.
DR   MIM; 612633; phenotype.
DR   neXtProt; NX_P27169; -.
DR   OpenTargets; ENSG00000005421; -.
DR   Orphanet; 803; Amyotrophic lateral sclerosis.
DR   PharmGKB; PA33529; -.
DR   VEuPathDB; HostDB:ENSG00000005421.8; -.
DR   eggNOG; ENOG502S3B5; Eukaryota.
DR   GeneTree; ENSGT00390000008932; -.
DR   HOGENOM; CLU_049839_0_1_1; -.
DR   InParanoid; P27169; -.
DR   OMA; TDEDNAM; -.
DR   OrthoDB; 888266at2759; -.
DR   PhylomeDB; P27169; -.
DR   TreeFam; TF322436; -.
DR   BRENDA; 3.1.1.2; 2681.
DR   BRENDA; 3.1.1.25; 2681.
DR   BRENDA; 3.1.8.1; 2681.
DR   PathwayCommons; P27169; -.
DR   Reactome; R-HSA-2142688; Synthesis of 5-eicosatetraenoic acids.
DR   SABIO-RK; P27169; -.
DR   SIGNOR; P27169; -.
DR   BioGRID-ORCS; 5444; 9 hits in 986 CRISPR screens.
DR   ChiTaRS; PON1; human.
DR   EvolutionaryTrace; P27169; -.
DR   GeneWiki; PON1; -.
DR   GenomeRNAi; 5444; -.
DR   Pharos; P27169; Tbio.
DR   PRO; PR:P27169; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P27169; protein.
DR   Bgee; ENSG00000005421; Expressed in right lobe of liver and 108 other tissues.
DR   ExpressionAtlas; P27169; baseline and differential.
DR   Genevisible; P27169; HS.
DR   GO; GO:0072562; C:blood microparticle; HDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0034364; C:high-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IEA:Ensembl.
DR   GO; GO:0034366; C:spherical high-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0102007; F:acyl-L-homoserine-lactone lactonohydrolase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004063; F:aryldialkylphosphatase activity; IDA:UniProtKB.
DR   GO; GO:0004064; F:arylesterase activity; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0005543; F:phospholipid binding; IDA:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0019439; P:aromatic compound catabolic process; IDA:BHF-UCL.
DR   GO; GO:0046395; P:carboxylic acid catabolic process; IDA:BHF-UCL.
DR   GO; GO:0008203; P:cholesterol metabolic process; IEA:Ensembl.
DR   GO; GO:0019372; P:lipoxygenase pathway; TAS:Reactome.
DR   GO; GO:0046434; P:organophosphate catabolic process; IDA:BHF-UCL.
DR   GO; GO:0046470; P:phosphatidylcholine metabolic process; IDA:BHF-UCL.
DR   GO; GO:0051099; P:positive regulation of binding; IDA:BHF-UCL.
DR   GO; GO:0010875; P:positive regulation of cholesterol efflux; IDA:BHF-UCL.
DR   GO; GO:0032411; P:positive regulation of transporter activity; IDA:BHF-UCL.
DR   GO; GO:0070542; P:response to fatty acid; IEA:Ensembl.
DR   GO; GO:1902617; P:response to fluoride; IEA:Ensembl.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IBA:GO_Central.
DR   Gene3D; 2.120.10.30; -; 1.
DR   InterPro; IPR011042; 6-blade_b-propeller_TolB-like.
DR   InterPro; IPR002640; Arylesterase.
DR   InterPro; IPR008363; Paraoxonase1.
DR   PANTHER; PTHR11799:SF16; PTHR11799:SF16; 1.
DR   Pfam; PF01731; Arylesterase; 1.
DR   PRINTS; PR01785; PARAOXONASE.
DR   PRINTS; PR01786; PARAOXONASE1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Direct protein sequencing; Disulfide bond;
KW   Glycoprotein; HDL; Hydrolase; Metal-binding; Reference proteome; Secreted;
KW   Signal.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:1718413,
FT                   ECO:0000269|PubMed:8292612, ECO:0000269|PubMed:8382160"
FT   CHAIN           2..355
FT                   /note="Serum paraoxonase/arylesterase 1"
FT                   /id="PRO_0000223281"
FT   SIGNAL          2..?
FT                   /note="Not cleaved"
FT   ACT_SITE        115
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000305"
FT   METAL           53
FT                   /note="Calcium 1; catalytic"
FT   METAL           54
FT                   /note="Calcium 2"
FT   METAL           117
FT                   /note="Calcium 2; via carbonyl oxygen"
FT   METAL           168
FT                   /note="Calcium 1; catalytic"
FT   METAL           169
FT                   /note="Calcium 2"
FT   METAL           224
FT                   /note="Calcium 1; catalytic"
FT   METAL           269
FT                   /note="Calcium 1; catalytic"
FT   METAL           270
FT                   /note="Calcium 1; catalytic"
FT   CARBOHYD        253
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:14760718,
FT                   ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:19159218"
FT   CARBOHYD        270
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        324
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952,
FT                   ECO:0000269|PubMed:19159218"
FT   DISULFID        42..353
FT                   /note="In form B"
FT                   /evidence="ECO:0000269|PubMed:15098021,
FT                   ECO:0000269|PubMed:8292612"
FT   VARIANT         55
FT                   /note="L -> M (in dbSNP:rs854560)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:1657140, ECO:0000269|PubMed:7916578,
FT                   ECO:0000269|PubMed:8393742, ECO:0000269|PubMed:8393745,
FT                   ECO:0000269|PubMed:8812495"
FT                   /id="VAR_006043"
FT   VARIANT         102
FT                   /note="I -> V (may be associated with an increased risk for
FT                   prostate cancer; associated with decreased activity;
FT                   dbSNP:rs72552787)"
FT                   /evidence="ECO:0000269|PubMed:12783936"
FT                   /id="VAR_015882"
FT   VARIANT         160
FT                   /note="R -> G (in dbSNP:rs13306698)"
FT                   /id="VAR_055342"
FT   VARIANT         192
FT                   /note="Q -> R (in allozyme B; increased arylesterase
FT                   activity; dbSNP:rs662)"
FT                   /evidence="ECO:0000269|PubMed:1657140,
FT                   ECO:0000269|PubMed:18987736, ECO:0000269|PubMed:7916578,
FT                   ECO:0000269|PubMed:8098250, ECO:0000269|PubMed:8393742,
FT                   ECO:0000269|PubMed:8393745, ECO:0000269|Ref.8"
FT                   /id="VAR_006044"
FT   MUTAGEN         20..21
FT                   /note="HQ->AA: The signal peptide is cleaved; not
FT                   associated with HDL."
FT                   /evidence="ECO:0000269|PubMed:10479665"
FT   MUTAGEN         115
FT                   /note="H->Q: Reduces activity 10000-fold."
FT                   /evidence="ECO:0000269|PubMed:15098021"
FT   MUTAGEN         134
FT                   /note="H->Q: Substantially reduced activity."
FT                   /evidence="ECO:0000269|PubMed:15098021"
FT   MUTAGEN         284
FT                   /note="C->A,S: No loss of activity."
FT                   /evidence="ECO:0000269|PubMed:7638166"
FT   HELIX           19..27
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   TURN            28..31
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          54..57
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          61..67
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          84..89
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          92..94
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          97..99
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          101..103
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          105..107
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   HELIX           109..111
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          114..121
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          127..133
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          140..147
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   TURN            148..151
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          152..159
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          165..174
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          177..183
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   HELIX           189..197
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          203..208
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          213..228
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          232..239
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   TURN            240..243
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          244..250
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          256..263
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          265..273
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   TURN            275..277
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          280..286
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   HELIX           288..292
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          302..308
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          312..314
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          316..323
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          325..328
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          330..337
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          340..348
FT                   /evidence="ECO:0007744|PDB:1V04"
FT   STRAND          350..353
FT                   /evidence="ECO:0007744|PDB:1V04"
SQ   SEQUENCE   355 AA;  39731 MW;  9B5895509166167E CRC64;
     MAKLIALTLL GMGLALFRNH QSSYQTRLNA LREVQPVELP NCNLVKGIET GSEDLEILPN
     GLAFISSGLK YPGIKSFNPN SPGKILLMDL NEEDPTVLEL GITGSKFDVS SFNPHGISTF
     TDEDNAMYLL VVNHPDAKST VELFKFQEEE KSLLHLKTIR HKLLPNLNDI VAVGPEHFYG
     TNDHYFLDPY LQSWEMYLGL AWSYVVYYSP SEVRVVAEGF DFANGINISP DGKYVYIAEL
     LAHKIHVYEK HANWTLTPLK SLDFNTLVDN ISVDPETGDL WVGCHPNGMK IFFYDSENPP
     ASEVLRIQNI LTEEPKVTQV YAENGTVLQG STVASVYKGK LLIGTVFHKA LYCEL
//
